|
|
Ocuphire Pharma Inc (NASDAQ: OCUP) |
|
Price: $1.1700
$-0.16 
-12.030%
|
| Day's High:
| $1.36
| Week Perf:
| -7.87 %
|
| Day's Low: |
$ 1.07 |
30 Day Perf: |
-14.6 % |
| Volume (M): |
677 |
52 Wk High: |
$ 2.34 |
| Volume (M$): |
$ 792 |
52 Wk Avg: |
$1.60 |
| Open: |
$1.33 |
52 Wk Low: |
$1.07 |
|
|
| Market Capitalization (Millions $) |
30 |
| Shares
Outstanding (Millions) |
26 |
| Employees |
15 |
| Revenues (TTM) (Millions $) |
18 |
| Net Income (TTM) (Millions $) |
-14 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Ocuphire Pharma Inc
Ocuphire Pharma Inc is a pharmaceutical company that specializes in developing and commercializing novel therapies for the treatment of various eye disorders. The company focuses on addressing unmet medical needs and providing innovative therapies to improve the lives of patients with ophthalmic conditions. Ocuphire Pharma is committed to advancing eye care through its research, development, and commercialization efforts.
Company Address: 37000 Grand River Avenue, Suite 120 Farmington Hills 48335 MI
Company Phone Number: 957-9024 Stock Exchange / Ticker: NASDAQ OCUP
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Merger and Acquisition
Published Tue, Oct 22 2024 8:06 PM UTC
Breaking News: Ocuphire Pharma Expands Horizons with Strategic Acquisition Focused on Gene Therapy for Rare Eye DisordersIn a significant development for the pharmaceutical industry, Ocuphire Pharma Inc. (NASDAQ: OCUP) has announced a strategic acquisition aimed at creating a leading, clinical-stage company dedicated to the advancement of gene therapy treatments for rare inh...
|
| Clinical Study
Published Mon, Sep 30 2024 12:00 PM UTC
In the esteemed annals of CSIMarket.com , it is our duty to present noteworthy advancements in the realm of pharmacology. Recent communications from Ocuphire Pharma Inc, a distinguished entity within the pharmaceutical sphere, disclose the publication of comprehensive results concerning Phase 3 clinical trials associated with the utilization of Phentolamine Ophthalmic Solut...
|
| Clinical Study
Published Fri, Sep 6 2024 12:44 AM UTC
Abstract Ocuphire Pharma has recently made significant strides in the pursuit of effective treatments for presbyopia, a common age-related vision condition affecting millions worldwide. This article highlights the initiation of the VEGA-3 Phase 3 clinical trial, which is evaluating the efficacy and safety of Phentolamine Ophthalmic Solution 0.75%. The trial is poised to pr...
|
| Clinical Study
Published Thu, Sep 5 2024 12:01 PM UTC
Presbyopia, the age-related decline in the eye s ability to focus on close objects, affects millions of individuals globally, leading to an increasing demand for effective treatment options. Ocuphire Pharma Inc., a clinical-stage ophthalmic company, is poised to make a significant impact in this area with the initiation of its VEGA-3 Phase 3 trial. The study focuses on the e...
|
Clinical Study
Innovative Approaches in Diabetic Retinopathy: Ocuphire Pharma?s Promising Candidate, APX3330'
CSIMarket.com '
The landscape of diabetic retinopathy (DR) treatment is poised for a potential breakthrough with the emergence of Ocuphire Pharma's novel small molecule therapeutic, APX3330. With a significant burden of disease affecting millions globally, advancements in DR therapies have been a focal point for researchers and clinicians alike. Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company specializing in the development of novel eye disorder therapeutics, is at the forefront of this research with its lead candidate APX3330. The company recently announced that updates on APX3330 will be prominently featured in two significant upcoming conferences: Clinical Trials at the Summit on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit on June 25-27 in Boston, Massachusetts.
Diabetic Retinopathy: An Overview'
Diabetic retinopathy is one of the leading causes of blindness in the working-age population worldwide. Characterized by damage to the retinal blood vessels, it results in leakage, hemorrhages, and, in advanced stages, the growth of abnormal new vessels. Despite current treatments like laser therapy, anti-VEGF injections, and corticosteroids, there remains an unmet need for effective and safe oral therapeutic options.
APX3330: Mechanism and Promising Data'
APX3330 represents a promising oral therapeutic candidate developed by Ocuphire Pharma. Functioning as an inhibitor of the APE1/Ref-1 protein, APX3330 targets the transcription factors NF-?B and HIF-1?, which are implicated in oxidative stress and inflammation - core pathways contributing to DR pathogenesis.
Ocuphire's clinical data thus far have highlighted the potential of APX3330 to not only slow down disease progression but also to improve visual and structural markers associated with DR. These promising results have garnered interest and anticipation within the ophthalmic community.
Upcoming Presentations and Significance'
The presentation at the Clinical Trials at the Summit on June 8 will provide preliminary insights into the recent clinical trials of APX3330, including safety profiles, efficacy endpoints, and patient tolerability. This meeting, well-known for its influential role in clinical dialog, serves as an excellent platform for Ocuphire to share their findings with experts and stakeholders.
Following this, the comprehensive detailing at the Retinal Imaging Biomarkers & Endpoints Summit from June 25-27 in Boston will focus on more robust imaging and biomarker data, potentially setting the stage for regulatory advancements and broader clinical acceptance. Given the multi-disciplinary audience, this presentation aims to underline the clinical applicability and transformative potential of APX3330.
Conclusion'
Ocuphire Pharma's continued development and forthcoming presentations on APX3330 could signify a paradigm shift in the management of diabetic retinopathy. Should the clinical efficacy and safety be corroborated in these and subsequent trials, APX3330 has the potential to fulfill an unmet need in DR therapeutic options, providing patients with a promising new avenue for treatment. The ophthalmology community looks forward with keen interest to the detailed presentations and data that will be shared at these pivotal conferences.
A Promising Horizon: Ocuphire Pharma?s APX3330 at the Forefront of Diabetic Retinopathy Treatment'This
Published Thu, Jun 6 2024 11:58 AM UTC
Innovative Approaches in Diabetic Retinopathy: Ocuphire Pharma?s Promising Candidate, APX3330 CSIMarket.com The landscape of diabetic retinopathy (DR) treatment is poised for a potential breakthrough with the emergence of Ocuphire Pharma s novel small molecule therapeutic, APX3330. With a significant burden of disease affecting millions globally, advancements in DR ther...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.58 $ |
| Revenues (TTM) |
0.71 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.6 $
|
| Book Value |
1.57 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.58 $
|
| Revenues (TTM) |
0.71 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.6 $
|
| Book Value |
1.57 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.67%